Marshall Wace, LLP Vertex Pharmaceuticals Inc Transaction History

Marshall Wace, LLP

$63.3 Billion
Q1 2024

A detailed history of Marshall Wace, LLP transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Marshall Wace, LLP holds 187,139 shares of VRTX stock, worth $88.7 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares

187,139

Previous 278,330 32.76%

Holding current value

$88.7 Million

Previous $113 Million 30.93%

% of portfolio

0.12%

Previous 0.2%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$407.69 - $446.08 $37.2 Million - $40.7 Million	-91,191 Reduced 32.76%	187,139 $78.2 Million
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $24.9 Million - $29.9 Million	72,715 Added 35.36%	278,330 $113 Million
Q3 2023 Nov 14, 2023	BUY	$338.18 - $362.46 $8.73 Million - $9.36 Million	25,815 Added 14.36%	205,615 $71.5 Million
Q2 2023 Aug 14, 2023	SELL	$314.42 - $351.91 $67.1 Million - $75.1 Million	-213,329 Reduced 54.26%	179,800 $63.3 Million
Q1 2023 May 15, 2023	SELL	$283.23 - $323.1 $4.78 Million - $5.46 Million	-16,892 Reduced 4.12%	393,129 $124 Million

Q4 2022 Feb 14, 2023	BUY	$285.76 - $321.48 $38.9 Million - $43.8 Million	136,169 Added 49.72%	410,021 $118 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $32.1 Million - $35.8 Million	-117,300 Reduced 29.99%	273,852 $79.3 Million
Q2 2022 Aug 15, 2022	BUY	$234.96 - $292.55 $91.9 Million - $114 Million	391,152 New	391,152 $110 Million
Q1 2022 May 16, 2022	SELL	$221.42 - $260.97 $33.2 Million - $39.1 Million	-150,000 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $72 Million - $90.9 Million	-406,678 Reduced 73.05%	150,000 $32.9 Million
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $1.04 Million - $1.16 Million	5,719 Added 1.04%	556,678 $101 Million
Q2 2021 Aug 13, 2021	BUY	$187.49 - $221.1 $68.3 Million - $80.5 Million	364,231 Added 195.06%	550,959 $111 Million
Q1 2021 May 17, 2021	SELL	$207.02 - $241.31 $2.66 Million - $3.1 Million	-12,859 Reduced 6.44%	186,728 $40.1 Million
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $32.7 Million - $43.7 Million	158,119 Added 381.3%	199,587 $47.2 Million
Q3 2020 Nov 16, 2020	BUY	$255.65 - $303.1 $9.42 Million - $11.2 Million	36,846 Added 797.19%	41,468 $11.3 Million
Q2 2020 Aug 13, 2020	BUY	$225.48 - $295.8 $897,861 - $1.18 Million	3,982 Added 622.19%	4,622 $1.34 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $7.37 Million - $9.14 Million	-36,885 Reduced 98.29%	640 $152,000
Q4 2019 Feb 14, 2020	SELL	$166.71 - $223.91 $6.01 Million - $8.07 Million	-36,033 Reduced 48.99%	37,525 $8.22 Million
Q3 2019 Nov 14, 2019	SELL	$166.23 - $187.09 $3.11 Million - $3.5 Million	-18,727 Reduced 20.29%	73,558 $12.5 Million
Q2 2019 Aug 14, 2019	BUY	$164.61 - $190.37 $4.95 Million - $5.72 Million	30,053 Added 48.29%	92,285 $16.9 Million
Q1 2019 May 14, 2019	BUY	$163.73 - $194.7 $110,026 - $130,838	672 Added 1.09%	62,232 $11.4 Million
Q4 2018 Feb 14, 2019	SELL	$151.91 - $192.21 $18.7 Million - $23.7 Million	-123,252 Reduced 66.69%	61,560 $10.2 Million
Q3 2018 Nov 14, 2018	SELL	$167.73 - $192.74 $32.1 Million - $36.9 Million	-191,673 Reduced 50.91%	184,812 $35.6 Million
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $50 Million - $58.3 Million	343,094 Added 1027.5%	376,485 $64 Million
Q1 2018 May 15, 2018	SELL	$151.6 - $177.13 $11.7 Million - $13.7 Million	-77,273 Reduced 69.83%	33,391 $5.44 Million
Q4 2017 Feb 14, 2018	BUY	$137.28 - $155.55 $12.2 Million - $13.9 Million	89,097 Added 413.12%	110,664 $16.6 Million
Q3 2017 Nov 13, 2017	BUY	$148.13 - $162.24 $3.19 Million - $3.5 Million	21,567	21,567 $3.28 Million

Others Institutions Holding VRTX

# of Institutions

1,624

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $122B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Vertex Pharmaceuticals Inc Transaction History